STAR 0502
Alternative Names: STAR-0502Latest Information Update: 12 Mar 2024
At a glance
- Originator Marengo Therapeutics
- Developer Ipsen; Marengo Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 26 Feb 2024 Early research in Solid tumours in USA (Parenteral) before February 2024 (Marengo Therapeutics pipeline, February 2024)